^
    1d
    GEM-BELACOMBOS: Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, PETHEMA Foundation
    New trial
    |
    B2M (Beta-2-microglobulin)
    |
    bortezomib • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    2d
    Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis (clinicaltrials.gov)
    P1, N=90, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jul 2028 --> Sep 2029 | Trial primary completion date: Jul 2028 --> Sep 2029
    Trial completion date • Trial primary completion date
    |
    Ordspono (odronextamab) • vonsetamig (REGN5459)
    5d
    MajesTEC-2: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Apr 2027 --> Oct 2025
    Trial primary completion date
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide • Ogsiveo (nirogacestat) • Tecvayli (teclistamab-cqyv)
    5d
    TRIlogy-5: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=700, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • ramantamig (JNJ-5322) • Tecvayli (teclistamab-cqyv)
    5d
    TEAM MDA5: Study of the Efficacy and Safety of a Bispecific Antibody, Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5 (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New P2 trial
    |
    IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    Tecvayli (teclistamab-cqyv)
    6d
    A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=40, Completed, Janssen Pharmaceutical K.K. | Active, not recruiting --> Completed
    Trial completion
    |
    Tecvayli (teclistamab-cqyv)
    6d
    MMRC Horizon One: RRMM (MMRC-099) (clinicaltrials.gov)
    P2, N=300, Active, not recruiting, Multiple Myeloma Research Consortium | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tecvayli (teclistamab-cqyv)
    7d
    A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 (clinicaltrials.gov)
    P3, N=255, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P3 trial
    |
    bortezomib • Darzalex (daratumumab) • pomalidomide
    7d
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2028 --> Dec 2028
    Trial completion date
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    8d
    A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA) (clinicaltrials.gov)
    P1/2, N=43, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    vonsetamig (REGN5459)
    14d
    POPLIN: Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) (clinicaltrials.gov)
    P4, N=30, Not yet recruiting, Regeneron Pharmaceuticals
    New P4 trial
    |
    Actemra IV (tocilizumab) • Lynozyfic (linvoseltamab-gcpt)
    14d
    A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) (clinicaltrials.gov)
    P1, N=32, Terminated, Sanofi | Phase classification: P1/2 --> P1
    Phase classification • First-in-human
    |
    SAR445514